The Ameliorative Effects of a Tocotrienol-Rich Fraction on the AGE-RAGE Axis and Hypertension in High-Fat-Diet-Fed Rats with Metabolic Syndrome

• Published in: Nutrients 2017-09, Vol.9 (9), p.984
• Main Authors: Cheng, Hong Sheng, Ton, So Ha, Tan, Joash Ban Lee, Abdul Kadir, Khalid
• Format: Article
• Language: English
• Subjects: Adipose tissue; Adiposity; advanced glycation end products; Advanced glycosylation end products; Animals; antioxidant activity; Antioxidants; Body Composition; Diet; Diet, High-Fat - adverse effects; Eating; Energy Intake; Fatty liver; Glucose Tolerance Test; glycation; Glycation End Products, Advanced - metabolism; glycemic control; glycohemoglobin; Glycosylation; Hemoglobin; High fat diet; histology; Humans; Hyperactivity; Hypercholesterolemia; Hypertension; Hypertension - chemically induced; laboratory animals; Liver; Male; males; Metabolic syndrome; myeloperoxidase; Oils & fats; Palm oil; palm oils; Peroxidase; peroxisome proliferator-activated receptor alpha; protective effect; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products - metabolism; Rodents; Steatosis; therapeutics; Tocopherols; tocotrienols; Tocotrienols - pharmacology; triacylglycerols; Weaning; Weight Gain
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu9090984

The clinical value of tocotrienols is increasingly appreciated because of the unique therapeutic effects that are not shared by tocopherols. However, their effect on metabolic syndrome is not well-established. This study aimed to investigate the effects of a tocotrienol-rich fraction (TRF) from palm oil in high-fat-diet-treated rats. Male, post-weaning Sprague Dawley rats were provided high-fat (60% kcal) diet for eight weeks followed by a TRF (60 mg/kg) treatment for another four weeks. Physical, metabolic, and histological changes were compared to those on control and high-fat diets respectively. High-fat feeding for eight weeks induced all hallmarks of metabolic syndrome. The TRF reversed systolic and diastolic hypertension, hypercholesterolemia, hepatic steatosis, impaired antioxidant defense, and myeloperoxidase hyperactivity triggered by the high-fat diet. It also conferred an inhibitory effect on protein glycation to reduce glycated hemoglobin A1c and advanced glycation end products (AGE). This was accompanied by the suppression of the receptor for advanced glycation end product (RAGE) expression in the liver. The treatment effects on visceral adiposity, glycemic control, triglyceride level, as well as peroxisome proliferator-activated receptor α and γ expression were negligible. To conclude, treatment with a TRF exhibited protective effects on the cardiovascular and liver health in addition to the amelioration of plasma redox imbalance and AGE-RAGE activation. Further investigation as a therapy for metabolic syndrome is therefore worthwhile.